May 16, 2012  |   
 
                    
                    
                    
                    
                    
                                        
                                                
Photo Credit: Shutterstock
 
 
 
 
The following is an excerpt from Born with a Junk Food Deficiency: How Flaks, Quacks, and Hacks Pimp the Public Health (Prometheus Books, 2012). Click here to order a copy of the book.
In his book
 Psychiatryland, psychiatrist Phillip Sinaikin 
recounts reading a scientific article in which it was debated whether a 
three-year-old girl who ran out into traffic had oppositional-defiant 
disorder or bipolar disorder, the latter marked by “grandiose delusions”
 that she was special and cars could not harm her.
1
How did the once modest medical specialty of child 
psychiatry become the aggressive “pediatric psychopharmacology” that 
finds ADHD, pediatric conduct disorder, depression, bipolar disorder, 
oppositional defiant disorder, mood disorders, obsessive-compulsive 
disorders, mixed manias, social phobia, anxiety, sleep disorders, 
borderline disorders, assorted “spectrum” disorders, irritability, 
aggression, pervasive development disorders, personality disorders, and 
even schizophrenia under every rock? And how did this branch of 
psychiatry come to find the answer to the “psychopathologies” in the 
name of the discipline itself: pediatric psychopharmacology? Just good 
marketing. Pharma is wooing the pediatric patient because that’s where 
the money is. Just like country and western songs about finding love 
where you can when there is no love to be found at home. Pharma has 
stopped finding “love” in the form of the new blockbuster drugs that 
catapulted it through the 1990s and 2000s. According to the Wall Street 
Journal, new drugs made Pharma only $4.3 billion in 2010 compared with 
$11.8 billion in 2005—a two-thirds drop.2
Doctors have a “growing fear of prescribing new drugs with unknown side effects,”3 explains
 the Journal, and the government is cracking down on illegal marketing. 
But also, private and government insurers are less willing to “cough up 
money for an expensive new drug—particularly when a cheap and reliable 
generic is available.4
It’s gotten so bad, AstraZeneca, whose controversial Seroquel® still
 makes $5.3 billion a year though it is no longer new, now conducts 
“payer excellence academies” to teach sales reps to sell insurers and 
state healthcare systems on its latest drugs.5 No
 wonder Pharma is finding “love” by prescribing drugs to the nation’s 
youngest (and oldest) patients, who are often behavior problems to their
 caregivers, who make few of their own drug decisions, and who are often
 on government health plans.
“Children are known to be compliant patients and that 
makes them a highly desirable market for drugs,” says former Pharma rep 
Gwen Olsen, author of Confessions of an Rx Drug Pusher.6 “Children
 are forced by school personnel to take their drugs, they are forced by 
their parents to take their drugs, and they are forced by their doctors 
to take their drugs. So, children are the ideal patient-type because 
they represent refilled prescription compliance and ‘longevity.’ In 
other words, they will be lifelong patients and repeat customers for 
Pharma.”
Just as it used to be said in obstetric circles, “Once a 
cesarean, always a cesarean,” it’s also true that “once a pediatric 
psychiatric patient, always a pediatric psychiatric patient.” Few, 
indeed, are kids who start out diagnosed and treated for ADHD, bipolar 
disorder, and other “psychopathologies” who end up on no drugs, 
psychologically fine, and ready to run for class president. Even if they
 outgrow their original diagnoses—a big “if” with a mental health 
history that follows them—the side effects from years of psychoactive 
drugs and their physical health on mental, social, and emotional 
development take their toll. Even children on allergy and asthma drugs, 
which are promoted for kids as young as age one, are now known to 
develop psychiatric side effects according to emerging research.7
Kids who start out with psychiatric diagnoses are not only
 lifers—they are expensive lifers usually shuttled into government 
programs that will pay for psychiatric drug “cocktails” that can 
approach $2,000 a month. What private insurer would pay $323 for an 
atypical antipsychotic like Zyprexa®, Geodon®, or Risperdal®, when a “typical” antipsychotic costs only about $40?8
Not all medical professionals agree with the slapdash 
cocktails. Panelists at the 2010 American Psychiatric Association (APA) 
meeting assailed Pharma for such “seat of the pants” drug combinations 
and called the industry nothing but a “marketing organization.”9 In
 a symposium about comparative drug effectiveness, a Canadian doctor 
castigated the FDA’s Jing Zhang, who had served as a panelist at the 
symposium, for his agency’s approval of drugs for “competitive reasons” 
rather than for patient health or effectiveness.10 Research
 presented at the 2010 APA meeting also questioned the psychiatric 
cocktails. When twenty-four patients on combinations of Seroquel, 
Zyprexa, and other antipsychotics were reduced to only one drug, there 
was no worsening of symptoms or increased hospitalizations (except in 
one case), and patients’ waist circumferences and triglycerides improved
 (a large waist circumference and high levels of triglycerides [fat] in 
the blood heighten one’s risk of developing diabetes and cardiovascular 
diseases).11 The drug cocktails were not working and were making patients worse by creating new medical problems.
But pediatric psychopharmacology is a billion-dollar 
business that sustains Pharma, Pharma investors on Wall Street, doctors,
 researchers, medical centers, clinical research organizations, medical 
journals, Pharma’s PR and ghostwriting firms, pharmacy benefits 
managers, and the FDA itself—which judges its value on how many drugs it
 approves. The only losers are kids given a probable life sentence of 
expensive and dangerous drugs, the families of these children, and the 
taxpayers and insured persons who pay for the drugs.
The father of pediatric psychopharmacology, Harvard child 
psychiatrist Joseph Biederman, is often called Joseph “Risperdal” 
Biederman, because he is credited with ballooning the diagnosis of 
bipolar disorder in children by as much as fortyfold.12 In
 2008, Biederman, a prolific author who has written five hundred 
scientific articles and seventy book chapters, was investigated by 
Congress for allegedly accepting Pharma money he didn’t disclose, and he
 agreed to suspend his industry-related activities.13 After
 a three-year investigation, Harvard “threw the book” at Biederman and 
two other professors: they were required to “refrain from all paid 
industry-sponsored outside activities for one year and comply with a 
two-year monitoring period afterward, during which they must obtain 
approval from the Medical School and Massachusetts General Hospital 
before engaging in any paid activities.” What a deterrent. They also 
face a “delay of consideration for promotion or advancement.”14
When it comes to grandiosity, Biederman seems a lot like 
the three-year- old who ran out in traffic. He not only served as the 
head of the Johnson & Johnson Center for the Study of Pediatric 
Psychopathology at Massachusetts General Hospital, whose stated goal was
 to “move forward the commercial goals of J. & J.”—the facility was 
his idea! 15 According to court-obtained documents, Biederman approached J. & J. with the money-making scheme.16 Biederman
 also promised the drug maker that upcoming studies of its popular child
 antipsychotic Risperdal would “support the safety and effectiveness of 
risperidone [Risperdal] in this age group.”17
The Johnson & Johnson Center for the Study of 
Pediatric Psychopathology netted a cool $700,000 in one year of 
operation, according to published reports, but a spokesman for Harvard 
Medical School said Harvard isn’t involved with Johnson & Johnson 
Center, even though the hospital where it operates, Massachusetts 
General, is a Harvard teaching hospital. “Harvard Medical School does 
not ‘own’ any of its teaching hospitals,” he told Bloomberg News. “While
 we are affiliated with them through academic appointments, all teaching
 hospitals are individually governed.”18
Many people are aware of such Pharma/academia 
arrangements, since the 1980 Bayh-Dole law allowed universities to 
operate as patent and profit mills for industries “commercializing and 
transferring” technology. But fewer realize how much taxpayer money is 
part of the play-to-pay. The government gave Biederman and a colleague 
$287 million in 2005—on top of their Pharma sinecures—to be administered
 by Massachusetts General Hospital. (No wonder Harvard keeps Biederman 
on.) Biederman also received $14,000 from Eli Lilly the same year he got
 a grant from the National Institutes of Health (NIH) to study Lilly’s 
ADHD drug, Strattera®. Why does the government fund 
researchers already funded by Pharma? Not only do these researchers not 
need our tax dollars; working for Pharma is an overt conflict of 
interest that contaminates scientific results.
Another master at playing both the Pharma and government 
sides of the street is psychiatrist Charles Nemeroff, former head of 
psychiatry at Emory University and also investigated by Congress for 
unreported Pharma money.
Nemeroff’s NIH grant was terminated after the probe, something that is rarely done with a government grant.19
According to the Chronicle of Higher Education, when 
Nemeroff was later under consideration to be the head of psychiatry at 
the University of Miami, the director of the National Institute of 
Mental Health (part of the NIH), Thomas Insel, MD, assured the medical 
school dean that if Nemeroff were hired, NIH money would follow, his 
prior problems notwithstanding. What’s a little congressional 
investigation? The reason for the largesse, according to the Chronicle, 
was that Nemeroff had gotten Insel a job at Emory when Insel lost his 
NIH position in 1994. Nor does the cronyism and revolving door stop 
there. Nemeroff serves on two NIH peer-review advisory panels that 
decide who else receives grant money, says the Chronicle, and Insel is 
personally involved with revising the National Institute of Mental 
Health’s “conflict of interest” rules.20
Insel is also known for advancing Pharma’s “SSRI 
deficiency/suicide hypothesis,” in which a decrease in antidepressant 
sales was—according to Pharma—resulting in suicides because people 
weren’t getting their drugs. “[The National Institute of Mental Health 
is] “looking at whether the decrease in SSRI [antidepressant] 
utilization might be associated with an increase in suicidality rather 
than a drop in suicide, and my expectation is that we may see an 
increase,” Insel told Psychiatric News, lamenting “the focus on risk and
 a neglect of benefit.”21
Antipsychotics for Everyone
When the atypical antipsychotics Zyprexa, Geodon, Risperdal, Abilify®,
 and Seroquel, for use in stabilizing schizophrenia, came into being in 
the 1990s, they were like the credit default swaps and collateralized 
debt obligations of the pharmaceutical world. No one knew exactly how 
they worked, how long they would work, or what the final effects of 
their wide use would be (as with many withdrawn drugs, FDA gives 
approval on the basis of information from short-term trials). But they 
could make a lot of quick money easily compared with old-fashioned 
products; they had government’s backing, and everyone was doing it!
Drug reps especially swarmed state agencies with many 
mentally disabled patients, including children. For example, Texas’s 
Medicaid program spent $557,256 for two months of pediatric Geodon 
prescriptions in 2005, according to court documents, and Geodon was not 
even approved for children at the time.22 Eighty-five percent of the state’s Risperdal prescriptions were paid by the state government, court documents also show.23 And Florida’s Medicaid program spent $935,584 for one year of Geodon.24 One
 hundred and eighteen prescriptions for Geodon were written in one day, 
according to the Tacoma News Tribune, at Western State mental hospital 
in Washington State. Asked why Pfizer reps made almost two hundred 
visits to the facility in four years, Pfizer spokesman Bryant Haskins 
told the Tribune, “That’s where our customers are.”25
Mental institution psychiatrists were not the only ones 
targeted. United States Department of Veterans Affairs psychiatrists 
said in a survey that they were contacted an average of fourteen times 
per year by Pharma reps and were invited to attend company-continuing 
medical education seminars.26 And court 
documents unsealed in South Carolina in 2009 show that Eli Lilly sales 
reps even used golf bets to push their atypical antipsychotic Zyprexa; 
one doctor agreed to start new patients on Zyprexa “for each time a 
sales representative parred.”27
But as state outlays for atypical antipsychotics grew 
twelvefold between 2000 and 2007, some states and whistle-blowers began 
bringing Pharma to court. In 2007, Bristol-Myers Squibb settled a 
federal suit for $515 million, brought by whistle-blowers in 
Massachusetts and Florida, which charged that the company marketed the 
antipsychotic Abilify for unapproved uses in children and the elderly, 
bilking taxpayers in the process.28 And the next 
year, Alaska won a precedent-setting $15 million settlement from Eli 
Lilly in a suit to recoup medical costs generated by Medicaid patients 
who developed diabetes while taking Zyprexa. Atypical antipsychotics are
 known to cause weight gain and glycemic changes that can lead to 
diabetes.29 Soon Idaho, Washington, 
Montana, Connecticut, California, Louisiana, Mississippi, New Mexico, 
New Hampshire, Pennsylvania, South Carolina, Utah, West Virginia, 
Arkansas, and Texas took Pharma to court for the “prescribathon,” which 
hit the poor, the mentally ill, children, and the elderly the hardest.30
Of course, as with credit default swaps and collateralized
 debt obligations (or the cases of Bernie Madoff or BP’s Deepwater 
Horizon or Enron), there were voices of dissent about the atypical 
revolution if people chose to listen. A National Institute of Mental 
Health study of children ages eight to nineteen with psychotic symptoms 
found Risperdal and Zyprexa were no more effective than the older 
antipsychotic Moban, but it caused such obesity that a safety panel 
ordered the children off the drugs.31 In just eight 
weeks, children gained an average of thirteen pounds on Zyprexa, nine 
pounds on Risperdal, and less than one pound on Moban.
“Kids at school were making fun of me,” said study 
participant Brandon Constantineau, who put on thirty-five pounds on 
Risperdal.32
Other studies, like one on Risperdal in the British 
medical journal Lancet and one on Zyprexa, Seroquel, and Risperdal in 
Alzheimer’s patients reported in the New England Journal of Medicine, 
also found that atypicals work no better than placebos.33 One
 study in the British Medical Journal found that Seroquel not only did 
not relieve agitation in Alzheimer’s patients, but that it “was [also] 
associated with significantly greater cognitive decline” than placebos.34 As with Risperdal, the drug made patients worse.
“The problem with these drugs [is] that we know that they 
are being used extensively off-label in nursing homes to sedate elderly 
patients with dementia and other types of disorders,” testified FDA drug
 reviewer David Graham, MD, during a congressional hearing.35 Graham
 is credited with exposing the dangers of Vioxx and other risky drugs 
approved by the FDA. “But the fact is, is that it increases mortality 
perhaps by 100 percent. It doubles mortality,” said Graham. “So I did a 
back-of-the-envelope calculation on this, and you have probably got 
15,000 elderly people in nursing homes dying each year from the 
off-label use of antipsychotic medications. . . . With every pill that 
gets dispensed in a nursing home, the drug company is laughing all the 
way to the bank.”36
Just like Wall Street and banking lobbyist and cronies 
“advised” the government on how to write the credit default and 
derivative rules under which they would be regulated, Pharma helps 
states regulate—and buy—its brand- name drugs. An Eli Lilly–backed 
company named Comprehensive Neuroscience has “helped” twenty-four states
 to use Zyprexa “properly,” reports the New York Times.37 “Doctors
 who veer from guidelines on dosage strengths and combinations of 
medications for Medicaid patients are sent ‘Dear Doctor’ letters 
pointing out that their prescribing patterns fall outside the norm,” it 
reports. Doctors are also notified if patients “are renewing 
prescriptions,” lest they have “setbacks in their condition.” One such 
program sends registered nurses to the homes of patients who are on 
expensive brand drugs to ensure “compliance”; that is, to make sure 
patients have not stopped taking the drugs.
Some states say they have saved money under Pharma’s 
guidance, but Wisconsin found that once it “placed restrictions on 
Zyprexa and three other antipsychotic drugs” and scrapped the 
Lilly-funded program, it lowered its antipsychotic bill by $4 million. 38
And then there’s the Texas Medication Algorithm Project, a
 “decision tree” developed by Pharma and Johnson & Johnson’s Robert 
Wood Johnson Foundation in 1995 to “help” the state buy its drugs. The 
algorithm rules required doctors to treat patients—surprise!—with the 
newest, most expensive drugs first, which ballooned Risperdal sales as 
well as other atypical antipsychotics.39
But in 2008, the Texas attorney general’s office charged 
Risperdal maker Janssen Pharmaceuticals, Inc., Johnson & Johnson’s 
antipsychotic drug unit, with fraud.40 Janssen
 defrauded the state of millions, said a civil suit, “with [its] 
sophisticated and fraudulent marketing scheme,” to “secure a spot for 
the drug, Risperdal, on the state’s Medicaid preferred drug list and on 
controversial medical protocols that determine which drugs are given to 
adults and children in state custody.” In addition to lavishing trips, 
perks, and kickbacks on Texas’s mental health officials to win drug 
sales, and disguising marketing as scientific research, the attorney 
general’s office charged that Janssen “paid third-party contractors and 
nonprofit groups to promote Risperdal . . . to give state mental health 
officials and lawmakers the perception that the drug had widespread 
support.”41
Such faux grassroots support from phony front groups has 
been cited in other lawsuits against Pharma. Whistle-blowers charge that
 Pfizer funded the National Alliance on Mental Illness (NAMI) to serve 
as a “Trojan horse” to sell Geodon in a complaint that led to 
forty-three states receiving givebacks and the largest criminal fine 
ever imposed in US history—$2.3 billion in 2009. 42
The National Alliance on Mental Illness calls itself a 
“nonprofit, grassroots, self-help, support and advocacy organization of 
consumers, families, and friends of people with severe mental 
illnesses,”43 but it has been 
investigated by Congress for undisclosed Pharma money and is considered 
by some to be a front organization. The Geodon complaint even cites 
jailed physician Richard Borison, who also worked with Seroquel and 
Neurontin, in the corruption.44
Of course, to lock in taxpayer funding of psychoactive 
drugs, especially for children, it takes more than “helping” state 
officials at the point of purchase (and sending zealous drug reps to 
state facilities where the “patients are”). Pharma also finances 
continuing medical education (CME) courses that reward credits doctors 
need to retain their state licenses. A CME course called Individualizing
 ADHD Pharmacotherapy with Disruptive Behavioral Disorders taught by the
 Johnson & Johnson–funded Robert L. Findling, MD, refers to 
Risperdal thirteen times.45 Another CME 
course that promoted Seroquel was “taught” by AstraZeneca staff and Dr. 
Nemeroff but was scrapped after the Accreditation Council for Continuing
 Medical Education found it “lacked sufficient information about 
possible adverse effects of treatment with atypical antipsychotic drugs;
 and failed to emphasize sufficiently the efficacy of alternative 
treatments.”46 The course was called Atypical Antipsychotics in Major Depressive Disorder: When Current Treatments Are Not Enough.
Pharma doctors also spread confidence about the drugs by 
publishing in medical journals like a Johnson & Johnson–subsidized 
article that upheld the “long-term safety and effectiveness of 
risperidone [Risperdal] for severe disruptive behaviors in children” in 
the Journal of the American Academy of Child & Adolescent 
Psychiatry. Despite thirty-one recorded child deaths, the drug was found
 to be safe, according to the article, on the basis of a one-year study.47
END NOTES 
CHAPTER 2. FRAGILE: HANDLE WITH RISPERDAL . . . AND SEROQUEL AND ZYPREXA AND GEODON
1. Martha Rosenberg, “Phillip Sinaikin, M.D., 
‘Psychiatryland’ Author, Explains How Psychiatry Is Broken,” Huffington 
Post, July 1, 2011, http://www.huffingtonpost.com/martha- 
rosenberg/phillip-sinaikin-psychiatryland_b_884863.html.
2. Jeanne Whalen, “Hurdles Multiply for Latest Drugs, Wall Street Journal, August 1, 2011.
3. Ibid. 4. Ibid. 5. Ibid.; Duff Wilson, “For $520 Million, AstraZeneca Will Settle Case over Marketing of
a Drug,” New York Times, April 26, 2010. 6. Gwen Olsen, “Drugging Our Children to Death,” Health News Digest, June 29, 2009,
http://healthnewsdigest.com/news/Guest_Columnist_710/Drugging_Our_Children_to_ Death.shtml (accessed September 25, 2011).
7. “FOX 5 Investigates Singulair,” Fox News, November 8, 2010.
8. Emily P. Walker, “Senators Question Use of Psych Drugs 
in Nursing Homes,” MedPage Today, August 15, 2011, 
http://www.medpagetoday.com/Geriatrics/Dementia/28052.
9. Martha Rosenberg, “Meeting the Drug Industry,” 
CounterPunch, June 4–6, 2010, http:// 
www.counterpunch.org/2010/06/04/meeting-the-drug-industry/.
10. Martha Rosenberg, “No Free Pens but Pharma Influence 
Still Felt at Psychi- atric Meeting,” AlterNet, June 2, 2010, 
http://blogs.alternet.org/speakeasy/2010/06/02/ 
no-free-pens-but-pharma-influence-still-felt-at-psychiatric-meeting/.
11. “Evaluating Antipsychotic Polypharmacy Regimens for 
Patients with Chronic Mental Illness,” poster from Maimonides Medical 
Center in Brooklyn, American Psychiatric Associa- tion 2010 meeting, New
 Orleans.
12. Gardiner Harris, “Research Center Tied to Drug Company,” New York Times, November 24, 2008.
13. Gardiner Harris and Benedict Carey, “Researchers Fail 
to Reveal Full Drug Pay,” New York Times, June 8, 2008; “Private Money, 
Public Disclosure,” Science, July 2009.
14. Xi Yu, “Three Professors Face Sanctions Following 
Harvard Medical School Inquiry Investigation by Medical School and 
Massachusetts General Hospital Punishes Psychiatrists Accused by 
Senator,” Harvard Crimson, July 2, 2011.
15. Harris, “Research Center Tied to Drug Company.”
16. Gardiner Harris, “Drug Maker Told Studies Would Aid It, Papers Say,” New York Times, March 19, 2009.
17. Ibid.
18. Rob Waters and Julie Ziegler, “Harvard Teaching 
Hospital Reviewing J&J Ties to Psychiatry Unit,” Bloomberg, November
 25, 2008.
19. Martha Rosenberg, “Why You Should Care about the 
University of Miami NIH Scandal, CounterPunch, June 22, 2010; Bradley F.
 Marple and Matthew W. Ryan, “Facing Conflicts: The Battle between 
Medicine and Industry,” ENT Today, April 2009, http://www. 
enttoday.org/details/article/497837/Facing_Conflicts_The_Battle_between_Medicine_and_
 Industry.html.
20. Ibid.
21. Jim Rosack, “New Data Show Declines in Antidepressant Prescribing,” Psychiatric News 40, no. 17 (September 2, 2005): 1.
22. United States District Court, District of 
Massachusetts Civil Action No. 08 CA 11318 DPW, Second Amended Complaint
 for False Claims Act Violations 31 U.S.C. § 3729, ET SEQ., March 13, 
2009.
23. Jim Edwards, “J&J and Risperdal: New Claims of 
Kickbacks and Fraudulent Mar- keting,” BNET, December 17, 2008, 
http://www.cbsnews.com/8301-505123_162-42840276/ 
j038j-and-risperdal-new-claims-of-kickbacks-and-fraudulent-marketing/ 
(accessed January 30, 2012).
24. United States District Court, District of Massachusetts Civil Action No. 08 CA 11318 DPW.
25. M. Alexander Otto, “Drugs Might Breed Violence,” News Tribune (Tacoma, WA), May 28, 2007.
26. Michael Sernyak and Robert Rosenheck, “Experience of 
VA Psychiatrists with Phar- maceutical Detailing of Antipsychotic 
Medications,” Psychiatric Services 58 (October 2007): 1292–96.
27. Margaret Cronin Fisk and Jef Feeley, “Lilly Paid 
Doctors to Prescribe Zyprexa, Bloom- berg, September 8, 2009, 
http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aHX 
OSlLoUMbM.
28. “$515 Million California Claims Drug Giant Bribed Docs to Prescribe,” Associated Press, March 23, 2011.
29. Alex Berenson, “Lilly Settles Alaska Suit over 
Zyprexa,” New York Times, March 26, 2008; Sanjay Gupta et al., “Atypical
 Antipsychotics and Glucose Dysregulation: A Series of 4 Cases,” Primary
 Care Companion, Journal of Clinical Psychiatry 3, no. 2 (2001): 61–65, 
http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC181163/.
30. Martha Rosenberg, “States Taking Pharma to Court for 
Risky Antipsychotic-Pre- scribing Spree,” AlterNet, October 19, 2008, 
http://www.alternet.org/health/103543.
31. Benedict Carey, “Risks Found for Youths in New Antipsychotics,” New York Times, September 15, 2008.
32. Ibid.
33. Peter Tyrer et al., “Risperidone, Haloperidol, and 
Placebo in the Treatment of Aggres- sive Challenging Behaviour in 
Patients with Intellectual Disability: A Randomised Controlled Trial,” 
Lancet 371, no. 9606 (January 5, 2008): 57–63; Lon S. Schneider et al., 
“Effectiveness of Atypical Antipsychotic Drugs in Patients with 
Alzheimer’s Disease,” New England Journal of Medicine 355 (October 12, 
2006): 1525–38.
34. Clive Ballard, “Quetiapine and Rivastigmine and 
Cognitive Decline in Alzheimer’s Disease: Randomised Double Blind 
Placebo Controlled Trial,” British Medical Journal 330 (Feb- ruary 18, 
2005): 874.
35. Ed Silverman, “Antipsychotics, Nursing Homes & 
Increased Risks,” Pharmalot, November 19, 2007, 
http://www.pharmalot.com/2007/11/antipsychotics-nursing-homes 
-expendable-patients/.
36. Ibid.
37. Stephanie Saul, “In Some States, Maker Oversees Use of Its Drug,” New York Times, March 23, 2007.
38. Ibid. 39. Edwards, “J&J and Risperdal.” 40. Emily Ramshaw, “Filing Alleges Drug Maker Defrauded Texas to Get on Medicaid
List,” Dallas Morning News, December 17, 2008. 41. Ibid.
42. United States District Court, District of Massachusetts Civil Action No. 08 CA 11318 DPW.
43. “Welcome to NAMI Arapahoe/Douglas Counties: A NAMI 
Colorado Affiliate,” National Alliance on Mental Illness, 
http://www.nami.org/MSTemplate.cfm?MicrositeID=257. 44. Jim Edwards, 
“Pfizer Used Docs Accused of Misconduct to Prep Geodon Submission to 
FDA,” BNET, September 22, 2009, 
http://www.cbsnews.com/8301-505123_162-42843001/
pfizer-used-docs-accused-of-misconduct-to-prep-geodon-submission-to-fda/.
 45. “Individualizing ADHD Pharmacotherapy in Patients with Disruptive 
Behavioral Disorders,” Medscape, December 28, 2007, 
http://www.medscape.org/viewprogram/8468
(accessed September 25, 2011). 46. Daniel Carlat, “New York Times Covers Industry Funding of CME,” Carlat Psychiatry
Blog, October 21, 2009, 
http://carlatpsychiatry.blogspot.com/2009/10/new-york-times-covers- 
industry-funding.html (accessed September 25, 2011).
47. Jan Croonenberghs et al., “Risperidone in Children 
with Disruptive Behavior Disor- ders and Subaverage Intelligence: A 
1-Year, Open-Label Study of 504 Patients,” Journal of the American 
Academy of Child & Adolescent Psychiatry 44, no. 1 (January 2005): 
64–72; Gardiner Harris, “Use of Antipsychotics in Children Is 
Criticized,” New York Times, November 18, 2008.
Martha Rosenberg 
frequently writes about the impact of the pharmaceutical, food and gun 
industries on public health. Her work has appeared in the Boston Globe, 
San Francisco Chronicle, Chicago Tribune and other outlets.